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Case-fatality rates for Plasmodium falciparum severe malaria (SM) remain unacceptably high in young 
children in Africa (1). Early detection and prompt 
treatment of SM are critical to improve the progno-
sis of sick children. Unfortunately, clinical signs and 
symptoms in many malaria patients, particularly 
early in the infection, may not adequately indicate 
whether the infection will trigger severe or life-threat-
ening disease. Moreover, in malaria-endemic areas, 
where immunity to malaria is progressively acquired, 
detecting peripheral P. falciparum parasitemia in sick 
children does not necessarily prove that malaria is the 
cause of the severe pathology observed, given that 
many persons may carry parasites without express-
ing clinical malarial disease (2).
Sequestration of P. falciparum–infected eryth-
rocytes (iEs) (3) in vital organs is considered a key 
pathogenic event leading to SM, as has been shown 
in postmortem parasite counts in patients who died 
with cerebral malaria (4,5). This extensive sequestra-
tion of parasitized erythrocytes in the microvascula-
ture, together with the production of inflammatory 
mediators, leads to the dysfunction of one or more pe-
ripheral organs, such as the lungs (acute respiratory 
distress syndrome), kidneys (acute kidney injury) or 
brain (coma) (6,7). This tissue-specific tropism of P. 
falciparum parasites is mediated by the P. falciparum 
erythrocyte membrane protein 1 (PfEMP1), which 
can bind to different host receptors on the capillary 
endothelium, uninfected erythrocytes, and platelets 
(8,9); such receptors include endothelial receptor of 
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Severe malaria (SM) is a major public health problem in 
malaria-endemic countries. Sequestration of Plasmo-
dium falciparum–infected erythrocytes in vital organs and 
the associated inflammation leads to organ dysfunction. 
MicroRNAs (miRNAs), which are rapidly released from 
damaged tissues into the host fluids, constitute a promis-
ing biomarker for the prognosis of SM. We applied next-
generation sequencing to evaluate the differential expres-
sion of miRNAs in SM and in uncomplicated malaria (UM). 
Six miRNAs were associated with in vitro P. falciparum 
cytoadhesion, severity in children, and P. falciparum bio-
mass. Relative expression of hsa-miR-4497 quantified 
by TaqMan-quantitative reverse transcription PCR was 
higher in plasma of children with SM than those with UM 
(p<0.048) and again correlated with P. falciparum biomass 
(p = 0.033). These findings suggest that different physio-
pathological processes in SM and UM lead to differential 
expression of miRNAs and pave the way for future studies 
to assess their prognostic value in malaria.
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No.2 February, 2021 431
protein C (ePCR), gC1qR, intercellular adhesion mol-
ecule-1, CD36, chondroitin sulfate A, or complement 
receptor 1 (10).
Efforts have been made to identify biomarkers 
of SM that could be used for early diagnosis and for 
reducing severity of disease (11). Several biomarkers 
related to endothelial activation and immune dys-
function have been associated with different malaria-
derived severe pathologies (11–14). Plasma level of 
histidine-rich protein 2 (HRP2), a parasite-specific 
protein secreted by the parasite during its blood 
cycle, has been used as a biomarker of total para-
site biomass (circulating and sequestered parasites) 
(15,16) and therefore as a prognostic marker of the to-
tal parasite biomass and as a better proxy marker for 
SM than peripheral parasitemia (16). Organ damage 
and pathological disease states have also been associ-
ated with the rapid release of microRNAs (miRNAs), 
a class of endogenous small noncoding RNAs (18–24 
nt), into circulation (17). Because secreted miRNAs 
can be detected in biologic fluids such as plasma (18), 
they are currently being explored (17) as promising 
noninvasive biomarkers to monitor organ functional-
ity and tissue pathophysiological status. The content 
of miRNAs in the host is influenced by host-pathogen 
interactions (19). Sequestration of erythrocytes in-
fected with P. berghei in mice brains has been dem-
onstrated to modify the miRNA expression in cells 
(20). Similarly, sequestration of P. vivax gametocytes 
in bone marrow has been associated with transcrip-
tional changes of miRNAs involved in erythropoiesis 
(21). The evidence suggests that Plasmodium parasites, 
although unable to produce miRNAs (22), could af-
fect the production of organ-specific host miRNAs, 
pointing toward the potential of these small mol-
ecules to detect SM associated organ injury (23) and 
to confirm the contribution of malaria in the chain of 
events leading to death through the analysis of post-
mortem tissues (23).
Our study hypothesis is that miRNA levels in 
plasma are differentially expressed among children 
with severe and uncomplicated malaria because of 
the parasite sequestration in vital organs of severely 
ill children. To identify promising biomarkers for SM, 
we conducted a small RNA next-generation sequenc-
ing study to select miRNAs that were differentially 
expressed by human brain endothelial (HBE) cells ex-
posed to P. falciparum iEs selected for cytoadhesion to 
ePCR, the main host receptor associated with SM (9), 
compared with HBE cells exposed to noncytoadher-
ent iEs and noninfected erythrocytes (niEs). We also 
compared children who had SM with children who 
had UM (Figure 1). miRNAs that were differentially 
expressed in both analyses, together with the P. falci-
parum biomass-associated miRNAs (correlation coef-
ficient >0.50 [24]), were quantitatively confirmed in 
Figure 1. Schematic representation of study design to identify miRNA-based biomarkers of SM. ePCR, endothelial protein-C 
receptor (a binding Plasmodium falciparum strain-FCR3); HRP2, histidine-rich protein 2;  iE, infected erythrocyte; miRNA, 
microRNA; niE, noninfected erythrocyte; SM, severe malaria; SS, severity symptoms; UM, uncomplicated malaria; 3D7, a 
nonbinding P. falciparum strain.
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an independent validation cohort set of children with 




Plasma samples used to assess miRNA levels were 
collected in 2 case–control studies conducted in Man-
hiça District in southern Mozambique during 2006 
(n = 113) and 2014 (n = 91). In brief, the cases were 
children <5 years of age admitted to Manhiça District 
Hospital for SM and controls were outpatient chil-
dren with UM (Appendix, https://wwwnc.cdc.gov/
EID/27/2/19-1795-App1.pdf). The National Mo-
zambican Ethical Review Committee (Mozambique) 
and Hospital Clínic (Barcelona, Spain) approved 
study protocols for each of the case–control studies. 
A signed written informed consent was obtained 
from each participant’s guardian or parent during the 
original studies.
Parasitological Determinations
We prepared thick and thin blood films to quantify 
P. falciparum parasitemia. We used approximately 
half of a 60μL dried blood drop on Whatman-903 
filter paper to extract parasite DNA and performed 
real-time quantitative PCR (qPCR) targeting the P. 
falciparum 18S rRNA gene (25,26). HRP2 levels were 
quantified using commercially available ELISA 
kits and an in-house highly sensitive quantitative 
bead suspension array (qSA) based on Luminex 
technology (Appendix).
P. falciparum Cytoadhesion Assays
We performed cytoadhesion assays to discover the 
differential expression of miRNAs (Appendix). HBE 
cells were incubated with P. falciparum iEs at the 
trophozoite stage of the ePCR binding FCR3 strain 
(ePCR-iE, which expresses the PfEPM1 protein that 
binds to ePCR receptor) and the 3D7 strain (3D7-iE, a 
strain without the protein that binds to ePCR recep-
tor). Noninfected erythrocytes were used as negative 
control. The cell-conditioned media of each group 
were collected after 1 h (t1) and 24 h of stimulation 
(t24) and subjected to RNA extraction followed by 
small-RNA sequencing.
Molecular Procedures, Gene Target Prediction  
and Data Analysis
RNA was extracted from cell-conditioned media (3 
mL) by using the miRNeasy tissues/cells kit (QIA-
GEN, https://www.qiagen.com) and from plasma 
samples (1 mL) by using the miRNeasy plasma/se-
rum kit, with the use of 5µg UltraPure glycogen/sam-
ple. Given that the plasma samples were conserved in 
heparin, RNA was precipitated with lithium chloride 
as described previously (27). Purified RNA was sub-
jected to library preparation, pooling, and sequenc-
ing using a HiSeq 2000 (Illumina, https://www.
illumina.com) platform, following the protocol for 
small RNAs (28) (Appendix). We used a previously 
published pipeline (28) to assess the sequencing qual-
ity, identification, and quantification of small RNAs, 
normalization and other species RNA contamination 
(Appendix). To detect miRNAs and isomiRs, reads 
were mapped to the precursors and annotated to 
miRNAs or isomiRs using miRBase version 21 with 
the miraligner (29). DESeq2 R package version 1.10.1 
(R3.3.2; https://www.r-project.org/about.html) (30) 
was used to perform an internal normalization.
In the 2014 study, we used 50 µL of plasma with 
no hemolysis for RNA extraction as described, then 
conducted qRT-PCR (Appendix). We calculated 
miRNA relative expression levels (RELs) by the 2−ΔCt 
method, where ∆Ct = cycle threshold (Ct) (miRNA) 
– mean Ct (endogenous controls; ECs), considering 
efficiencies of 100% for all the miRNAs and ECs (31).
The selected miRNAs were screened through 
different gene target prediction programs such as 
DIANA-microT-CDS (http://www.microrna.gr/ 
microT-CDS), MiRDIP (http://ophid.utoronto.ca/ 
mirDIP), MirGate (http://mirgate.bioinfo.cnio.es), and 
TargetScan (http://www.targetscan.org) (Appendix). 
We assessed differential expression of miRNAs and 
isomiRs using DESEq2 and IsomiRs packages in R (29,32) 
(Appendix). All statistical analyses were performed 
using R version 3.3.2, and graphs were prepared with 
GraphPad version 6 (https://www.graphpad.com).
Results
Discovery Phase
miRNA Expression by HBE Cells
The ePCR binding P. falciparum strain (FCR3; ePCR-
iE) showed higher levels of cytoadhesion to HBE cells 
(mean 32.60, SD 4.87 iE/500 cells) than a nonbinding 
P. falciparum (3D7; 3D7-iE) strain (mean 3.20, SD 1.06 
iE/500 cells; p = 0.001) and noninfected erythrocytes 
(mean 3.12, SD 0.39 iE/500 cells; p = 0.001) (Appen-
dix Figure 1). We sequenced 3 replicates of the media 
collected from each cytoadhesion assay after 1 h (t1) 
and 24 h (t24), giving a total of >200 million reads/
lane, with a mean of 12.10 million reads (SD 13.31) per 
sample (Table 1; Figure 2, panel A; Appendix Table 
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1). The mean percentage of miRNAs in the media 
samples analyzed was 4.01% (SD 2.93%); a mean of 
203 (SD 93.82, range 101–465) distinct miRNAs were 
detected (Appendix Table 1). The 10 most expressed 
miRNAs for all samples at t1 and t24 time points are 
described in Figure 2, panel B. No contamination with 
RNA from other species was observed.
One hour after incubating the HBE cells with P. 
falciparum infected and noninfected erythrocytes, 111 
miRNAs were found to be differentially expressed in 
cell-condition media of niE and ePCR-iE; 76 of them 
were downregulated and 35 upregulated in ePCR-
iE compared with niE (Figure 2, panel C; Appendix 
Table 2). At this same time point, 100 miRNAs were 
differentially expressed in cell-condition media of 
3D7-iE and ePCR-iE; 67 were downregulated and 
33 upregulated in ePCR-iE compared with 3D7-iE 
(Figure 2, panel D; Appendix Table 3). Overall, 89 
miRNAs were differentially expressed in ePCR-
iE compared with both niE and 3D7-iE; 28 of those 
were upregulated and 61 downregulated in ePCR-iE. 
There were no differentially expressed miRNAs be-
tween niE and 3D7-iE cell-condition media. At t24, 
only hsa-miR-451a was significantly upregulated in 
cell-condition media of ePCR-iE with respect to niE 
(p<0.001) and 3D7-iE (p = 0.023). We found no signifi-
cantly different miRNAs between niE and 3D7-iE cell-
condition media. All differentially expressed isomiRs 
originated from the selected miRNAs; none of them 
presented any modifications in the seed region.
miRNAs Expression in Plasmas from Children with  
Malaria of Varying Severity
Out of 113 plasma samples collected from children 
with SM (N = 57) and UM (N = 56) in Mozambique in 
2006, 11 samples were discarded, 5 because of hemo-
lysis (OD414>0.2) (33) and 6 because no peak was ob-
served between 133–150 nt (typical size for miRNAs 
 
Table 1. Quality control and mapped reads in different species of small RNAs from cell-conditioned media of human brain endothelial 
cells and plasma samples in children with uncomplicated and severe malaria, Mozambique* 
Read type 
Cell condition 
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4.87 (5.88) 3.59 (2.62) 
















*Reads were obtained from cell-conditioned media of human brain endothelial cells exposed to cytoadherent P. falciparum–infected and noninfected 
erythrocytes, and plasma of Mozambique children with SM and UM. Three replicates of the media were collected from each cytoadhesion assay after 1 
(t1) and 24 (t24) hours. ePCR-iE, adherent FCR3 expression endothelial receptor of protein C-infected erythrocytes; miRNA, microRNA; niE, noninfected 
erythrocytes; SM, severe malaria; UM, uncomplicated malaria; 3D7-iE, nonadherent 3D7-infected erythrocytes.  
†Reads after filtering low quality, low complexity, and short (<18-nt) sequences. 
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plus library adaptors) on the bioanalyzer results after 
library preparation. Among the 102 sequenced sam-
ples (SM = 53, UM = 49), 19 samples (9 SM, 10 UM) 
were further excluded because of the low number of 
miRNA reads (<10,000 reads). In total, samples from 
83 children (44 with SM and 39 with UM) were in-
cluded in the analysis (Table 2). 
The sequencing of the 83 plasma samples yield-
ed a mean of 9.42 (SD 6.4) million reads per sample 
(Table 1; Figure 2, panel A; Appendix Table 4). The 
mean percentage of miRNAs per plasma samples was 
20.5% (SD 13.2%), with a mean of 395 (SD 169, range 
116–786) distinct miRNAs detected (Appendix Table 
4). The total number of miRNAs detected across sam-
ples was 1,450. The 10 most expressed miRNAs can 
be found in Figure 2, panel B. No contamination with 
RNA from other species was observed.
We found hsa-miR-122–5p upregulated in chil-
dren with SM (Table 3). In the subanalysis by signs of 
severity, 5 miRNAs were associated with severe ane-
mia (SA), prostration, and acute respiratory distress 
(ARD) (Table 3). Twelve miRNAs were associated 
Figure 2. RNA sequencing of 
human brain endothelial (HBE) cell 
media and plasma from children 
recruited in 2006, Mozambique. 
A) Percentage of mapped reads 
in different species of small 
RNAs, for both in vitro and ex 
vivo approaches. B) Ten most 
expressed miRNAs in HBE cell 
medias and plasmas. Color-coded 
cells show the percentage of each 
assay/condition (columns) for 
each miRNA (rows). C) Volcano 
plot of differentially expressed 
miRNAs in cell-condition media of 
niEs versus cell-condition media 
of iEs with the FCR3-ePCR strain 
(ePCR-iE) incubated with HBE 
cells. D) Volcano plot of differentially 
expressed miRNAs in cell-condition 
media of iEs with 3D7 strain (3D7-
iE) versus cell-condition media of 
iEs with the FCR3-ePCR strain 
(ePCR-iE) incubated with HBE 
cells. Comparisons depicted in C 
and D were adjusted for multiple 
testing by the Benjamini-Hochberg 
method. Negative log2-fold change 
indicates overexpression in ePCR-
iE samples. ePCR, endothelial 
protein-C receptor (a binding 
Plasmodium falciparum strain); 
HRP2, histidine-rich protein 2; 
iE, infected erythrocyte; miRNA, 
microRNA; SM, severe malaria; UM, 
uncomplicated malaria. 
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with PM-agglutination and cytoadhesion to g1CqR 
(Table 3). We observed no associations between miR-
NA counts and other cytoadhesion data such as roset-
ting and binding to CD36 and to CD54. After adjusting 
for multiple comparisons, we found 3/1,450 miRNAs 
identified in RNA sequencing data, hsa-miR-10b-5p, 
hsa-miR-378a-3p, and hsa-miR-4497, correlated with 
HRP2 levels determined by qSA Spearman analysis 
(Figure 3). We observed similar correlations when 
HRP2 levels were determined by ELISA (Appendix 
Table 5). miRNAs were neither associated with hepa-
tomegaly nor with splenomegaly. All differentially 
expressed isomiRs between children with SM and 
those with UM belong to the differentially expressed 
miRNAs, with no modifications in the seed region.
Validation Cohort
Among the 89 miRNAs differentially expressed in 
cell-condition media of HBE cells exposed to niE and 
3D7-iE compared with ePCR-iE, we confirmed 5 miR-
NAs to be differentially expressed between children 
with SM and UM. These 5 miRNAs (hsa-miR-122–5p, 
hsa-miR-320a, hsa-miR-1246, hsa-miR-1290 and hsa-
miR-3158–3p), along with hsa-miR-4497 miRNA, 
which had a correlation coefficient with HRP2 >0.5 
(Figure 3), were selected for TaqMan qRT-PCR vali-
dation in an independent cohort of children with SM 
and UM recruited in 2014. Among the 91 plasma sam-
ples collected from these children, 21 were discarded 
because of hemolysis (OD414>0.2) (33). Of the 70 re-
maining samples, 40 were collected from children 
with SM and 30 from children with UM (Table 2). 
All samples tested by qRT-PCR amplified the ex-
ogenous control (ath-miR-159a) with a Ct value<18 
and a coefficient of variance (CV) <5%, suggesting 
the correct RNA extraction and cDNA preparation. 
We selected 3 ECs, hsa-miR-191–5p (CV = 4.8%, base-
Mean = 3953.3, log2-fold change [FC] −0.02, SD 0.56), 
hsa-miR-30d-5p (CV = 4.9%, baseMean = 14172.31, 
FC 0.01, SD 0.61), and hsa-miR-148a-3p (CV = 5%, 
 
Table 2. Characteristics of children with severe and uncomplicated malaria recruited for case–control studies in 2006 and 2014, 
Mozambique* 
Characteristic 
2006  2014 
UM, n = 39 SM, n = 44 p value UM, n = 30 SM, n = 40 p value 
Age, y, mean (SD)† 2.3 (1.1) 2.4 (1.3) 0.671  2.2 (1.3) 2.8 (1.2) 0.419 
Sex, no. (%)  
  
     
 M 24 (62) 28 (64) 1.000  18 (60) 21 (52.5) 0.532 
 F 15 (38) 16 (36)   12 (40) 19 (47.5)  
HRP2, ng/mL, GM (SD) 71.3 (10.7) 331.4 (40.7) <0.001  24.1 (4.9) 78.7 (12.2) 0.038 









Splenomegaly, no. (%) 
  
     
 No 33 (85) 21 (48) 0.001  ND 27 (67.5) NA 
 Yes 6 (15) 23 (52)   ND 13 (32.5)  
Hepatomegaly, no. (%) 
  
     
 No 38 (97) 35 (80) 0.016  ND 35 (87.5) NA 
 Yes 1 (3) 9 (20)   ND 5 (12.5)  
Hyperlactatemia, no. (%) 
  
     
 No 10 (26) 5 (11) 0.152  26 (86.7) 27 (67.5) 0.064 
 Yes 29 (74) 39 (89)   4 (13.3) 13 (32.5)  
Temperature, ºC, mean (SD) 38.0 (1.6) 38.5 (1.1) 0.093  38.0 (1.3) 38.2 (1.4) 0.437 
Weight, kg, mean (SD) 11.3 (2.8) 11.0 (2.8) 0.599  12.3 (2.9) 12.7 (3.3) 0.476 
Platelets, 109/L, mean (SD) 156.7 (86.8) 115.8 (66.8) 0.018  149.0 (89.7) 95.3 (69.3) 0.001 
Glucose, mM, mean (SD)‡ 6.2 (1.5) 5.9 (1.8) 0.391  6.6 (1.3) 6.0 (2.6) 0.165 
WBC, 109/L, mean (SD) 9.9 (4.1) 10.2 (3.9) 0.774  9.7 (3.8) 9.6 (5.0) 0.929 
Neutrophils, %, mean (SD)§ 54.1 (16.7) 54.4 (14.3) 0.940  50.7 (20.6) 58.9 (13.7) 0.447 
Lymphocytes, %, mean (SD)¶ 39.4 (17.9) 36.3 (12.6) 0.374  26.1 (17.1) 25.6 (12.2) 0.995 
Lactate, mM, mean (SD) 3.0 (1.7) 4.7 (3.6) 0.009  2.8 (2.2) 3.6 (2.4) 0.035 
Severe malaria syndromes, no. (%) 
  
    
 
 Prostration  33 (75.0)    30 (75.0) 
 
 Acute respiratory distress  18 (40.9)   19 (47.5) 
 
 Severe anemia  17 (38.6)    7 (17.5) 
 
 Multiple seizures  11 (25.0)    24 (60.0) 
 
 Cerebral malaria  2 (4.5)    7 (17.5) 
 
 Hypoglycemia  2 (4.5)    2 (5.0) 
 
*Data were gathered in a discovery study in 2006 and validation study in 2014. GM, geometric mean; HRP2, histidine-rich protein 2: NA, not applicable; 
ND, not determined; SM, severe malaria; UM, uncomplicated malaria; WBC, white blood cells. 
†No data for 1 sample (UM = 1) in 2014 study. 
‡No data for 3 samples (SM = 2; UM = 1) in 2014 study. 
§No data for 4 samples (SM = 4) in 2014 study. 
¶No data for 3 samples (SM = 3) in 2014 study.
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baseMean = 111593.08, FC 0.11, SD 0.82) as a panel 
for qRT-PCR analysis. Among these, the NormFinder 
stability value was 0.044 for the combination of hsa-
miR-30d-5p and hsa-miR-191–5p, and thus we select-
ed those 2 ECs. No statistically significant differences 
were found when we compared Ct values of the ex-
ogenous controls and 2 endogenous controls between 
SM and UM samples (Appendix Figure 2). We per-
formed standard curves for all miRNAs (ECs and se-
lected miRNAs), giving efficiencies of 91.1%–103.8% 
(Appendix Table 6), which were assumed as 100% to 
calculate the relative expression values using the 2−ΔCt 
method (31).
The relative expression levels of hsa-miR-3158–3p 
and hsa-miR-4497 were significantly higher in chil-
dren with SM than UM (p<0.05) (Figure 4). We found 
that hsa-miR-3158–3p levels were higher in children 
who had prostration, multiple seizures, and ARD 
compared with those who had UM (p<0.05; Figure 
5). Severe anemia and ARD symptoms were associ-
ated with higher hsa-miR-4497 levels (p<0.05; Figure 
5). No such associations were observed for cerebral 
malaria and hypoglycemia. RELs of hsa-miR-3158–3p 
and hsa-miR-4497 were found positively correlated 
with HRP2 levels quantified by qSA (p<0.05; Figure 
6). Similar correlations were observed when HRP2 
levels were determined by ELISA (Appendix Table 5).
miRNA Gene Target Prediction
We identified a total of 87 putative targets for hsa-
miR-3158–3p and hsa-miR-4497 miRNAs, none of 
which were shared by both miRNAs (Appendix Table 
7). We predicted 45 experimentally validated mRNA 
targets for hsa-miR-3158–3p and 42 for hsa-miR-4497; 
the predicted targets were found to be involved in a 
broad range of biologic processes (Appendix Table 
8). However, significance was lost when adjusted by 
the Benjamini-Hochberg method; none of the target 
genes were clustered under the KEGG pathway with 
p<0.05.
Discussion
Because of their specificity to cell type (17), microR-
NAs can reflect disease states and organ damage. 
Consequently, they have the potential to provide a 
new screening method for early detection of patho-
logical P. falciparum sequestration and could be-
come an effective prognosis tool for severe malaria. 
 
Table 3. Association of miRNA levels with severe malaria, symptoms of severity, and Plasmodium falciparum cytoadhesion among 
children with uncomplicated and severe malaria, Mozambique* 
Characteristic miRNA baseMean log2-fold change Adjusted p value 
Clinical data 
   
 SM, n = 44 vs. 39 UM    
  All hsa-miR-122-5p 19,929.69 1.67 0.001 
  SA, n = 17 vs. 39 UM 
   
 
hsa-miR-4492 17.34 2.81 0.046 
 hsa-miR-4497 293.66 2.18 0.046 
  Prostration, n = 33 vs. 39 UM 
   
 
hsa-miR-122-5p 20,677 1.89 0.001  
hsa-miR-6087 5.36 2.39 0.033  
hsa-miR-511-5p 126.67 1.36 0.040 
  Acidosis or respiratory distress, n = 18 vs. 39 UM 
 
 
hsa-miR-122-5p 13,367.43 2.21 <0.001  
hsa-miR-4497 272.39 2.05 0.07 
Cytoadhesion data 
 Platelet-mediated agglutination, n = 50 vs. 19 UM 
  
 
hsa-miR-3158-3p 1,180.96 −2.26 <0.001  
hsa-miR-320a 22,005.69 −1.48 0.001  
hsa-miR-4492 18.33 2.78 0.002  
hsa-miR-1290 1,011.34 −1.38 0.014  
hsa-miR-320b 1,191.44 −1.23 0.014  
hsa-miR-320c 408.32 −1.29 0.014  
hsa-miR-1246 3,907.45 −1.32 0.019  
hsa-miR-6741-5p 48.11 −1.81 0.023  
hsa-miR-1228-5p 82.73 −1.88 0.023  
hsa-miR-3195 16.35 2.21 0.023  
hsa-miR-7706 334.86 −1.00 0.023 
 gC1qR, n = 35 vs. 34 UM 
   
 hsa-miR-1-3p 622.35 2.09 0.003 
*Positive fold change indicates overexpression in severe malaria and symptoms of severity compared to UM as well as parasites showing cytoadhesion 
compared to none. Total number of miRNAs in RNA sequencing data was 1,450. p value adjusted for multiple testing by the Benjamini-Hochberg method. 
baseMean, mean normalized expression of the miRNAs in all the samples; miRNA, microRNA; SA, severe anemia, SM, severe malaria; UM, 
uncomplicated malaria.  
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Moreover, the detection of miRNAs associated with 
organ damage in host biofluids may provide an al-
ternative to postmortem autopsies for determining 
the presence of parasites in host vital organs. This ap-
proach creates new opportunities to develop malaria 
diagnostic tools that can guide treatment decisions, 
and to understand the role of human miRNAs in sev-
eral disease conditions (23).
In the discovery phase, 89 miRNAs were found 
to be differentially expressed in the media of HBE 
cells after incubation with an ePCR-cytoadherent P. 
falciparum strain compared with noncytoadherent 
parasites and noninfected erythrocytes. In addition, 
15 miRNAs in plasma samples obtained from chil-
dren were associated with SM, with specific severity 
symptoms, and with the cytoadherent P. falciparum 
Figure 3. Spearman correlations between HRP2 levels and relative expression levels (RELs) of 3 miRNA in plasma samples from 
children with malaria, 2006, Mozambique. A) hsa-miR-10b-5p; B) hsa-miR-378a-3p; C) hsa-miR-4497. HRP2 levels and miRNA RELs 
were log transformed. The correlation analysis was adjusted for multiple testing by the Benjamini-Hochberg method. HRP2, histidine-
rich protein 2; miRNA, microRNA; REL, relative expression levels.
Figure 4. MiRNA validation in plasma samples of children with malaria, 2014, Mozambique. A) hsa-miR-122-5p; B) hsa-miR-320a; 
C) hsa-miR-1246; D) hsa-miR-1290; E) hsa-miR-3158-3p; F) hsa-miR-4497. RELs were calculated with respect to the mean of 2 
endogenous controls (hsa-miR-30d-5p and hsa-miR-191–5p) and compared between children with SM and UM. Statistical differences 
were obtained by using the Mann-Whitney U test. Error bars represent medians and interquartile ranges. HRP2, histidine-rich protein 2; 
miRNA, microRNA; REL, relative expression levels; SM, severe malaria; UM, uncomplicated malaria.
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phenotype, compared with UM and noncytoadher-
ent parasites. In the validation phase, we confirmed 
the higher abundance of hsa-miR-3158–3p and hsa-
miR-4497 in children with SM than in children with 
UM. Prostration, multiple seizures, SA, and ARD 
symptoms of severity were associated with higher 
levels of hsa-miR-3158–3p and hsa-miR-4497. hsa-
miR-4497 levels were also positively correlated with 
the parasite biomass as quantified by the levels of 
HRP2 in both the discovery and validation phases. 
Overall, these findings suggest that different physio-
pathological processes in SM and UM lead to differ-
ential expression of miRNAs in plasma.
HBE cells released a high number of the miRNAs 
when they were stimulated with an ePCR binding P. 
falciparum strain within the first hour of incubation. Af-
ter 24 hours, the system stabilized; 1 miRNA (hsa-miR-
451a) was found at higher levels in cell-conditioned 
media of HBE cells incubated with an ePCR binding 
strain than in cells stimulated with nonadherent (3D7-
iE) or noninfected erythrocytes. miR-451 has been im-
plicated in translocation to form a chimera with Plas-
modium mRNAs to block their translation (34) and was 
also found to be abundant in sickle erythrocytes (35). 
In addition, it has been shown that parasites could 
reduce miR-451 levels in host fluids (36). However, 
this finding was not confirmed in plasmas from the 
children in this study. Five miRNA levels were higher 
in children with SM and severity symptoms (prostra-
tion, SA, and ARD) than in children with UM. P. fal-
ciparum cytoadhesion phenotypes (PM-agglutination 
and cytoadhesion to gC1qR) were also associated with 
the differential expression of miRNAs, suggesting that 
the interaction between PfEMP1 and host receptors 
leads to the secretion to plasma of specific miRNAs. 
Moreover, 3 miRNAs (hsa-miR-10b-5p, hsa-miR-378a-
3p, and hsa-miR-4497) were positively correlated with 
HRP2 levels.
We selected 6 candidate miRNAs identified in 
the discovery phase to determine the validity of the 
previous results in an independent cohort of children 
in Mozambique. The relative expression of hsa-miR-
3158–3p and hsa-miR-4497 was significantly higher in 
children with SM than in those with UM; hsa-miR-
3158–3p levels were higher in children with prostra-
tion, multiple seizures, and ARD, and hsa-miR-4497 
in children with SA and ARD. To our knowledge, 
hsa-miR-3158–3p, which is widely expressed in 
skin, spleen, kidney, and brain tissues (37), has been 
associated with bipolar disorders (38) but not with 
Figure 5. Association of microRNA levels with symptoms of severity in children with malaria, Mozambique, 2014. A) hsa-miR-122-5p; 
B) hsa-miR-320a; C) hsa-miR-1246; D) hsa-miR-1290; E) hsa-miR-3158-3p; F) hsa-miR-4497. RELs were calculated with respect to 
the mean of 2 endogenous controls (hsa-miR-30d-5p and hsa-miR-191–5p) and compared between children with UM and symptoms 
of severity. Distributions were compared using Mann-Whitney U test. Error bars represent medians and interquartile ranges. p values 
are shown for significant comparisons. ARD, acidosis or acute respiratory distress; MS, multiple seizures; P, prostration; REL, relative 
expression levels; SA, severe anemia; UM, uncomplicated malaria.
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other infectious diseases. Further validation is re-
quired for hsa-miR-3158–3p because the levels of this 
miRNA were found to be downregulated in the plas-
ma from children recruited in 2006 with positive PM-
agglutination compared with no PM-agglutination, a 
P. falciparum cytoadhesion phenotype which has been 
associated with malaria severity (39). However, the 
positive correlation of hsa-miR-4497 with HRP2 lev-
els, which was consistently observed in the cohorts of 
children from 2006 and 2014, suggested that increas-
ing parasite biomass associated with parasite seques-
tration may lead to higher levels of secretion of this 
specific miRNA by damaged tissues. The miRNA 
hsa-miR-4497 is widely expressed in the lymph nodes 
and spleen, kidney, and liver tissues (37). Overall, this 
study shows that hsa-miR-4497, which is also associ-
ated with SM, might be an interesting proxy marker 
of malaria severity. However, hsa-miR-4497 has been 
identified as a tumor suppressor (40) and associated 
with Mycobacterium tuberculosis infection (41). There-
fore, longitudinal studies are required to assess the 
prognostic value of this miRNA, as well as to estimate 
its differential expression in children with severity 
due to nonmalarial infections.
Few of the most expressed miRNAs found in 
our study, which represent 70% of the total miRNA 
counts in plasma samples, have been previously re-
ported as highly abundant in plasma samples (28,42). 
According to public data deposited in the miRmine 
database (43), hsa-miR-486–5p and hsa-miR-451a are 
the 2 most abundant miRNAs in plasma; both were 
among the 10 most expressed miRNAs in our study. 
Although no data are available on miRNAs from cell-
conditioned media of HBE cells, miRNA data from 
other cell types, such as primary tissue explants, pri-
mary stromal cells, and breast cancer cell lines, also 
show low miRNA yield (44), similar to this study. 
Our observation indicates that RNA sequencing data 
obtained in this study is of good quality and can be 
used for posterior analysis with high confidence. 
The first limitation of our study is that we used 
only HBE cells and ePCR binding parasites for the 
in vitro assay and therefore may have missed miR-
NAs produced by other parasite-host interactions 
contributing to SM. Second, plasma samples used in 
this study were collected retrospectively. Therefore, 
factors before small RNA sequencing and TaqMan- 
qRT-PCR, such as time taken between centrifugation, 
Figure 6. Spearman correlations between HRP2 levels and microRNA RELs in plasma samples from children with malaria, 
Mozambique, 2014. A) hsa-miR-122-5p; B) hsa-miR-320a; C) hsa-miR-1246; D) hsa-miR-1290; E) hsa-miR-3158-3p; F) hsa-miR-4497. 
HRP2 levels and microRNA RELs were log transformed. HRP2, histidine-rich protein 2; REL, relative expression levels.
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storage, and storage temperature, might have varied 
among the samples, affecting miRNA plasma levels 
(45,46). However, confirmation of findings in both the 
study cohorts suggest a minimal effect of preanalysis 
conditions in the results. Third, variations in the num-
ber of miRNAs identified in replicates of in vitro ex-
periments may have led to the loss of some miRNAs. 
Fourth, the lack of tissue samples from organs with 
P. falciparum sequestration restricted the histological 
confirmation of identified miRNAs, and the presence 
of co-infections other than blood culture positive bac-
teremia cannot be neglected in the studied plasma 
samples. Finally, the association of each miRNA with 
specific symptoms that are part of the SM case defini-
tion may need further validation using a larger sam-
ple size, considering that our numbers were relatively 
small for individual SM criteria. In addition, future 
studies using machine-learning approaches would 
enable the identification of a combination of miRNAs 
that may detect SM pathologies.
In conclusion, the profiling of miRNAs in media 
from HBE cells after incubation with a cytoadherent 
P. falciparum strain and in plasma from children with 
different clinical manifestations enabled us to iden-
tify promising miRNA candidates for characterizing 
severe malaria, specifically hsa-miR-4497. This study 
is a base for future analyses to understand the value 
of these miRNAs as a prognostic biomarker and for 
disentangling the etiology of SM.
Acknowledgments
We thank the children who participated in the study; the 
staff of the Manhiça District Hospital; the clinical officers, 
field supervisors, and data managers; G. Cabrera,  
L. Mussacate, N. Ernesto José, and A. Nhabomba for their 
contribution to the collection of parasites; and L. Puyol 
for her laboratory management, as well as everyone who 
supported this study directly or indirectly. We also thank 
Ruhi Sikka, Varun Sharma, Rebecca Smith-Aguasca, Malia 
Skjefte, and Catriona Patterson for their useful comments 
on this manuscript.
This work was supported by the Instituto de Salud Carlos III 
(PI13/01478 cofunded by the Fondo Europeo de Desarrollo 
Regional [FEDER], grant no. CES10/021-I3SNS to A.M. and 
no. CP11/00269 from the Miguel Servet program to Q.B.). 
H.G. was supported by the Science and Engineering Research 
Board (SERB), Department of Science & Technology,  
Government of India (Overseas Postdoctoral Fellowship,  
SB/OS/PDF043/201516), January 2017–January 2019. IS-
Global is a member of the CERCA Programme, Generalitat 
de Catalunya (http://cerca.cat/en/suma). CISM is  
supported by the Government of Mozambique and the 
Spanish Agency for International Development (AECID). 
This research is part of ISGlobal’s Program on the Molecular 
Mechanisms of Malaria, which is partially supported by the 
Fundación Ramón Areces.
H.G. and M.R. carried out the molecular analysis and 
results interpretation and wrote the first draft of this 
manuscript. P.C. also carried out molecular analysis and 
conducted cytoadhesion assays. A.S., R.V., L.M., and I.C. 
participated in fieldwork; collected clinical and  
epidemiological data, plasma samples, and dried blood 
drop filter papers; and performed microscopy. A.J., 
X.M.V., and D.B. participated in HRP2 analysis. M.R., P.C., 
H.G., L.P., A.B., and M.B. participated in bioinformatics 
and statistical analyses. Q.B. and A.M. participated in the 
study design, supervision, funding acquisition, project  
administration and coordinated all the stages of the  
project. All authors reviewed and approved the final 
manuscript. The datasets analyzed in this study are  
available from the corresponding author on request.
About the Author
Dr. Gupta is a molecular biologist and an early career ma-
laria disease researcher. His research focuses on host and 
parasite factors associated with severe malaria, and on the 
use of molecular tools for the active surveillance of emerg-
ing drug resistance, gene deletions, and afebrile malaria in 
malaria-endemic regions.
References
  1. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, 
Chhaganlal KD, et al.; AQUAMAT group. Artesunate versus 
quinine in the treatment of severe falciparum malaria in 
African children (AQUAMAT): an open-label, randomised 
trial. Lancet. 2010;376:1647–57. https://doi.org/10.1016/
S0140-6736(10)61924-1
  2. Gravenor MB, van Hensbroek MB, Kwiatkowski D.  
Estimating sequestered parasite population dynamics in 
cerebral malaria. Proc Natl Acad Sci U S A. 1998;95:7620–4. 
https://doi.org/10.1073/pnas.95.13.7620
  3. Miller LH, Baruch DI, Marsh K, Doumbo OK. The 
pathogenic basis of malaria. Nature. 2002;415:673–9.  
https://doi.org/10.1038/415673a
  4. Dorovini-Zis K, Schmidt K, Huynh H, Fu W, Whitten RO, 
Milner D, et al. The neuropathology of fatal cerebral malaria 
in Malawian children. Am J Pathol. 2011;178:2146–58. 
https://doi.org/10.1016/j.ajpath.2011.01.016
  5. Nagatake T, Hoang VT, Tegoshi T, Rabbege J, Ann TK, 
Aikawa M. Pathology of falciparum malaria in Vietnam. Am 
J Trop Med Hyg. 1992;47:259–64. https://doi.org/10.4269/
ajtmh.1992.47.259
  6. Milner DA Jr, Whitten RO, Kamiza S, Carr R, Liomba G,  
Dzamalala C, et al. The systemic pathology of cerebral  
malaria in African children. Front Cell Infect Microbiol. 
2014;4:104. https://doi.org/10.3389/fcimb.2014.00104
  7. White NJ, Turner GD, Day NP, Dondorp AM. Lethal 
malaria: Marchiafava and Bignami were right. J Infect Dis. 
2013;208:192–8. https://doi.org/10.1093/infdis/jit116
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No.2 February, 2021 441
MicroRNA of P. falciparum Severe Malaria
  8. Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion 
of Plasmodium falciparum-infected erythrocytes to human 
cells: molecular mechanisms and therapeutic implications. 
Expert Rev Mol Med. 2009;11:e16. https://doi.org/10.1017/
S1462399409001082
  9.  Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, 
Avril M, et al. Severe malaria is associated with  
parasite binding to endothelial protein C receptor. Nature. 
2013;498:502–5. https://doi.org/10.1038/nature12216
10. Jensen AR, Adams Y, Hviid L. Cerebral Plasmodium  
falciparum malaria: The role of PfEMP1 in its pathogenesis 
and immunity, and PfEMP1-based vaccines to prevent it. 
Immunol Rev. 2020;293:230–52. https://doi.org/10.1111/
imr.12807
11. Sahu PK, Satpathi S, Behera PK, Mishra SK, Mohanty S,  
Wassmer SC. Pathogenesis of cerebral malaria: new  
diagnostic tools, biomarkers, and therapeutic approaches.  
Front Cell Infect Microbiol. 2015;5:75. https://doi.org/ 
10.3389/fcimb.2015.00075
12. Erdman LK, Petes C, Lu Z, Dhabangi A, Musoke C,  
Cserti-Gazdewich CM, et al. Chitinase 3-like 1 is induced by 
Plasmodium falciparum malaria and predicts outcome of  
cerebral malaria and severe malarial anaemia in a case– 
control study of African children. Malar J. 2014;13:279. 
https://doi.org/10.1186/1475-2875-13-279
13. Lucchi NW, Jain V, Wilson NO, Singh N, Udhayakumar V, 
Stiles JK. Potential serological biomarkers of  
cerebral malaria. Dis Markers. 2011;31:327–35.  
https://doi.org/10.1155/2011/345706
14. Tahar R, Albergaria C, Zeghidour N, Ngane VF, Basco LK, 
Roussilhon C. Plasma levels of eight different mediators 
and their potential as biomarkers of various clinical malaria 
conditions in African children. Malar J. 2016;15:337.  
https://doi.org/10.1186/s12936-016-1378-3
15. Dondorp AM, Desakorn V, Pongtavornpinyo W,  
Sahassananda D, Silamut K, Chotivanich K, et al.  
Estimation of the total parasite biomass in acute falciparum 
malaria from plasma PfHRP2. PLoS Med. 2005;2:e204. 
https://doi.org/10.1371/journal.pmed.0020204
16. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, 
Mtove G, White LJ, Olaosebikan R, et al. Diagnosing severe 
falciparum malaria in parasitemic African children: a  
prospective evaluation of plasma PfHRP2 measurement. 
PLoS Med. 2012;9:e1001297. https://doi.org/10.1371/ 
journal.pmed.1001297
17. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, 
Sood AK, Calin GA. MicroRNAs in body fluids—the mix of 
hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467–
77. https://doi.org/10.1038/nrclinonc.2011.76
18. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, 
Pogosova-Agadjanyan EL, et al. Circulating microRNAs as 
stable blood-based markers for cancer detection. Proc Natl 
Acad Sci U S A. 2008;105:10513–8. https://doi.org/10.1073/
pnas.0804549105
19. Hakimi MA, Cannella D. Apicomplexan parasites and  
subversion of the host cell microRNA pathway. Trends Parasitol. 
 2011;27:481–6. https://doi.org/10.1016/j.pt.2011.07.001
20. El-Assaad F, Hempel C, Combes V, Mitchell AJ, Ball HJ, 
Kurtzhals JA, et al. Differential microRNA expression in  
experimental cerebral and noncerebral malaria. Infect Immun. 
2011;79:2379–84. https://doi.org/10.1128/IAI.01136-10
21.  Baro B, Deroost K, Raiol T, Brito M, Almeida AC,  
de Menezes-Neto A, et al. Plasmodium vivax gametocytes in 
the bone marrow of an acute malaria patient and changes 
in the erythroid miRNA profile. PLoS Negl Trop Dis. 2017; 
11:e0005365. https://doi.org/10.1371/journal.pntd.0005365
22. Xue X, Zhang Q, Huang Y, Feng L, Pan W. No miRNA were 
found in Plasmodium and the ones identified in erythrocytes 
could not be correlated with infection. Malar J. 2008;7:47. 
https://doi.org/10.1186/1475-2875-7-47
23. Rubio M, Bassat Q, Estivill X, Mayor A. Tying malaria and 
microRNAs: from the biology to future diagnostic  
perspectives. Malar J. 2016;15:167. https://doi.org/10.1186/
s12936-016-1222-9
24. StatsTutor. Spearman’s correlation. 2011 [cited 2020 Nov 23]. 
http://www.statstutor.ac.uk/resources/uploaded/ 
spearmans.pdf
25. Mayor A, Serra-Casas E, Bardají A, Sanz S, Puyol L, Cisteró P, 
et al. Sub-microscopic infections and long-term recrudescence 
of Plasmodium falciparum in Mozambican pregnant women. 
Malar J. 2009;8:9. https://doi.org/10.1186/1475-2875-8-9
26. Taylor SM, Mayor A, Mombo-Ngoma G, Kenguele HM,  
Ouédraogo S, Ndam NT, et al. A quality control program 
within a clinical trial consortium for PCR protocols to detect 
Plasmodium species. J Clin Microbiol. 2014;52:2144–9.  
https://doi.org/10.1128/JCM.00565-14
27. Wang J, Chen J, Chang P, LeBlanc A, Li D, Abbruzzesse JL,  
et al. MicroRNAs in plasma of pancreatic ductal  
adenocarcinoma patients as novel blood-based biomarkers  
of disease. Cancer Prev Res (Phila). 2009;2:807–13.  
https://doi.org/10.1158/1940-6207.CAPR-09-0094
28. Rubio M, Bustamante M, Hernandez-Ferrer C,  
Fernandez-Orth D, Pantano L, Sarria Y, et al. Circulating 
miRNAs, isomiRs, and small RNA clusters in human  
plasma and breast milk. PLoS One. 2018;13:e0193527. 
https://doi.org/10.1371/journal.pone.0193527
29. Pantano L, Estivill X, Martí E. SeqBuster, a bioinformatic  
tool for the processing and analysis of small RNAs  
datasets, reveals ubiquitous miRNA modifications in  
human embryonic cells. Nucleic Acids Res. 2010;38:e34. 
https://doi.org/10.1093/nar/gkp1127
30. Love MI, Huber W, Anders S. Moderated estimation of 
fold change and dispersion for RNA-seq data with DESeq2. 
Genome Biol. 2014;15:550. https://doi.org/10.1186/ 
s13059-014-0550-8
31. Marabita F, de Candia P, Torri A, Tegnér J, Abrignani S, 
Rossi RL. Normalization of circulating microRNA expression 
data obtained by quantitative real-time RT-PCR. Brief  
Bioinform. 2016;17:204–12. https://doi.org/10.1093/bib/
bbv056
32. Pantano L, Estivill X, Martí E. A non-biased framework for 
the annotation and classification of the non-miRNA small 
RNA transcriptome. Bioinformatics. 2011;27:3202–3.  
https://doi.org/10.1093/bioinformatics/btr527
33. Kirschner MB, Edelman JJ, Kao SC, Vallely MP,  
van Zandwijk N, Reid G. The impact of hemolysis on  
cell-free microRNA biomarkers. Front Genet. 2013;4:94. 
https://doi.org/10.3389/fgene.2013.00094
34. LaMonte G, Philip N, Reardon J, Lacsina JR, Majoros W,  
Chapman L, et al. Translocation of sickle cell erythrocyte  
microRNAs into Plasmodium falciparum inhibits parasite  
translation and contributes to malaria resistance. Cell Host  
Microbe. 2012;12:187–99. https://doi.org/10.1016/j.chom. 
2012.06.007
35. Chen SY, Wang Y, Telen MJ, Chi JT. The genomic analysis 
of erythrocyte microRNA expression in sickle cell diseases. 
PLoS One. 2008;3:e2360. https://doi.org/10.1371/ 
journal.pone.0002360
36. Rathjen T, Nicol C, McConkey G, Dalmay T. Analysis of 
short RNAs in the malaria parasite and its red blood cell 
host. FEBS Lett. 2006;580:5185–8. https://doi.org/10.1016/ 
j.febslet.2006.08.063
RESEARCH
442 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No.2 February, 2021
37. Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, 
Pallasch C, et al. Distribution of miRNA expression across 
human tissues. Nucleic Acids Res. 2016;44:3865–77.  
https://doi.org/10.1093/nar/gkw116
38. Maffioletti E, Cattaneo A, Rosso G, Maina G, Maj C,  
Gennarelli M, et al. Peripheral whole blood microRNA 
alterations in major depression and bipolar disorder.  
J Affect Disord. 2016;200:250–8. https://doi.org/10.1016/ 
j.jad.2016.04.021
39. Mayor A, Hafiz A, Bassat Q, Rovira-Vallbona E, Sanz S,  
Machevo S, et al. Association of severe malaria outcomes 
with platelet-mediated clumping and adhesion to a novel 
host receptor. PLoS One. 2011;6:e19422.  
https://doi.org/10.1371/journal.pone.0019422
40. Chen X, Zhang L, Tang S. MicroRNA-4497 functions as a 
tumor suppressor in laryngeal squamous cell carcinoma 
via negatively modulation the GBX2. Auris Nasus Larynx. 
2019;46:106–13. https://doi.org/10.1016/j.anl.2018.05.005
41. Das K, Saikolappan S, Dhandayuthapani S. Differential 
expression of miRNAs by macrophages infected with  
virulent and avirulent Mycobacterium tuberculosis.  
Tuberculosis (Edinb). 2013;93(Suppl):S47–50.  
https://doi.org/10.1016/S1472-9792(13)70010-6
42. Tonge DP, Gant TW. What is normal? Next generation 
sequencing-driven analysis of the human circulating  
miRNAOme. BMC Mol Biol. 2016;17:4. https://doi.
org/10.1186/s12867-016-0057-9
43. Panwar B, Omenn GS, Guan Y. miRmine: a database of hu-
man miRNA expression profiles. Bioinformatics. 2017;33:1554–
60. https://doi.org/10.1093/bioinformatics/btx019
44. Glynn CL, Khan S, Kerin MJ, Dwyer RM. Isolation of  
secreted microRNAs (miRNAs) from cell-conditioned  
media. MicroRNA. 2013;2:14–9. https://doi.
org/10.2174/2211536611302010003
45. Glinge C, Clauss S, Boddum K, Jabbari R, Jabbari J,  
Risgaard B, et al. Stability of circulating blood-based  
microRNAs—pre-analytic methodological considerations. 
PLoS One. 2017;12:e0167969. https://doi.org/10.1371/ 
journal.pone.0167969
46. Sourvinou IS, Markou A, Lianidou ES. Quantification of 
circulating miRNAs in plasma: effect of preanalytical and 
analytical parameters on their isolation and stability. J Mol 
Diagn. 2013;15:827–34. https://doi.org/10.1016/ 
j.jmoldx.2013.07.005
Address for correspondence: Himanshu Gupta, ISGlobal, Hospital 
Clínic, Universitat de Barcelona, Carrer Rosselló 153 (CEK Bldg), 


















Peste des petits ruminants
botulism
Rickettsia
Yersinia
rabies
influenza
Chagas disease
Malaria
Brucella
Artemisinin
Mange
Orientia tsutsugamushi
syphilis
quarantine
sapovirus
chimera
Leishmaniasis
Ebola
Coxiella burnetii
Borrelia
orf
Babesia
Kaposi
Vibrio vulnificus
yaws
variola
vaccination
rotavirus
Q fever
Plasmodium knowlesi
meliodosis
Franciscella tularensis
cholera
featured 
monthly in
Merkel cells
measles
knemidocoptic mange
tularemia
kobuvirus
Rickettsia
Eptesicus fuscus syncytium
Campylobacter
pertussis
Bordetella
Quinine
Acinetobacter
Calcivirus
Herpesvirus
Norovirus
Leptospira
Ehrlichia
pertactin
Verona integron
Anopheles
quarantine
Klebsiella
typhus
Candida
Lyssavirus
Glanders
hemozoin
Aspergillus
Diphtheria
O’nyong-nyong virus
http://wwwnc.cdc.gov/eid/articles/etymologia 
